Antaros is now moving its PDGFRβ probing tracer, ATH001, into clinical phase. This is an important step in addressing the unmet need for quality non-invasive biomarkers for fibrotic disease. Fibrosis is a common pathway in many diseases affecting organs such as the liver, kidney, and heart. The need for non-invasive and sensitive biomarkers that can detect changes in fibrosis development and therefore be used to assess response to interventions is high.
Per Hagmar, Chief Executive Officer, Antaros Tracer: “It is extremely exciting moving into the clinical phase. We are very proud to address this important area in dire need of better treatments”.
“ATH001 is a very promising tracer for understanding ongoing fibrogenesis”, says Olof Eriksson, Chief Scientific Officer, Antaros Tracer AB. “It has the potential to really progress how we, non-invasively, assess progression of fibrotic disease and response to therapy, which are key for enabling the development of novel antifibrotic drugs, initially in MASH, PSC and Crohn’s disease”.
PDGFRβ – an important radiopharmaceutical target for fibrogenesis
ATH001 is a radiopharmaceutical that is being developed to probe the presence of platelet-derived growth factor receptor beta (PDGFRβ) using PET. PDGFRβ is a marker of ongoing fibrogenesis in tissue. ATH001 enables tissue specific quantification of active fibrotic disease and shows strong promise as a non-invasive tool for imaging fibrogenesis and could provide valuable insights in the search for new treatments for fibrotic diseases (including metabolic dysfunction-associated steatohepatitis (MASH (previously NASH)), primary sclerosing cholangitis (PSC) and fibrostenotic Crohn’s disease (CD)).
ATH001 – a tracer for fibrogenesis
Fibrosis can occur in almost any organ or tissue in the body and is a leading cause of morbidity and mortality. Current methods to assess fibrosis are either invasive or insufficiently sensitive for detecting ongoing fibrosis production (fibrogenesis). Thus, there is an unmet need for non-invasive and sensitive biomarkers that can help detect, stage, and elucidate the molecular processes that drive the pathology of fibrosis and enable the assessment of treatment effects in the search for novel antifibrotic drugs aiming to turn down fibrogenesis.
About Antaros Tracer
Antaros Tracer is a sister company to Antaros Medical, formed to ensure an expedited and focused development of new Positron Emission Tomography (PET) tracers to be used as important biomarkers in drug development studies. Current disease area focus is fibrotic disease and immune-system activation in immune-oncology, inflammatory disease, and immunology.
For more information: Antaros Tracer – Antaros Medical
About Antaros Medical
Antaros Medical is pioneering imaging methodologies to design and deliver clinical imaging studies for improved, evidence-based decision making in drug development. The company is specialised in cardiorenal & metabolic diseases and oncology. The company has a global network of collaboration partners and customers, including both Big Pharma and Biotechs, and is a partner in several European collaboration initiatives such as Innovative Medicines Initiative (IMI) and COST. Antaros Medical has delivered small complex, mechanistic studies as well as multi-centre clinical trials worldwide utilising our innovative imaging methods. The global headquarter and imaging CoreLab are based in Sweden. In addition, a USA subsidiary is recently opened. For more information visit antarosmedical.com